Mindray Medical International Limited is China's largest medical equipment manufacturer, developing, manufacturing, and marketing.
Mindray , founded in January, 1999 and headquartered in Shenzhen, is a medical equipment and solution provider. The founder is Li Xiting. Listed on the SZSE on October 16, 2018, the company's major shareholders are Shenzhen Mindray PE Investment Fund Co., Ltd., Mindray Medical Sweden AB and Zhejiang Greenlander Information Technology Co., Ltd. Rivals that have direct and indirect competition with Mindray include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
We-Linking Raised Over CNY 10 Mn in Angel Round
Intraoperative Neurophysiological Monitoring Equipment Developer NeuroFlag Closed An Angel Round
913 companies have been investigated by public funds since the second quarter, and the six top flow fund managers focus on the leaders of subdivided industries
Several new funds have actively picked up chips to speed up the pace of position building
2022 China AI Health 30 Report
The 14th five year development plan of Shenzhen national high tech Zone aims to reach 200 listed enterprises in the zone by 2025
The third top stream of 100 billion was born! Ge Lan was "more down, more buy", and the scale soared by 10 billion
There are more than 3000 reception institutions a year, and Mindray medical has become the most concerned company in 2021
During the year, the issuance of A-share convertible bonds was "cold" and the scale of bond issuance on the gem rose against the trend
Beijing Pilots The DRG External Payment Mode
DRG refers to the diagnosis-related group used to classify the patient and set up a system to ensure the care provided is necessary. The National Healthcare Security Administration will pay the hospital a predetermined amount according to a patient’s DRG.
Jul 16, 2022 12:12 AM
Anxin Securities: the performance of Mindray medical is in line with expectations, and the six-month target price is 440.8 yuan
Aeroengine power: the subsidiary intends to acquire some assets of Liming technology
Yongmaotai: the net profit in the first half of the year was 122 million yuan, a year-on-year increase of 76%
Northbound capital increased its position by 26 shares for 7 consecutive weeks
Zhongyuan expressway: the net profit in the first half of the year was 642 million yuan, turning losses into profits year-on-year
Pharmaceutical and medical stocks fell sharply in early trading, and Hengrui pharmaceutical fell more than 9%
In the second quarter, the public fund's heavy position stocks are released, and Guizhou Maotai is still the largest heavy position stocks